- cafead   Jun 26, 2023 at 09:12: PM
via Agios Pharmaceuticals Inc (NASDAQ: AGIO) announced that the Phase 2 portion of the global Phase 2/3 RISE UP study of mitapivat in sickle cell disease met its primary endpoint of hemoglobin response.
article source
article source